Efficacy of folic acid as an adjunct to lithium therapy on manic-like behaviors, oxidative stress and inflammatory parameters in an animal model of mania. 2020

Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
Translational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil.

Evaluate the efficacy of folic acid (FA) as a therapeutic adjunct to lithium (Li) on the manic-like behaviors as well as parameters of oxidative stress and inflammation in an animal model of mania induced by m-amphetamine (m-AMPH). Wistar rats first received m-AMPH or saline (NaCl 0.9%, Sal) for 14 days. Between the 8th and 14th day, rats were treated with water, Li, FA or a combination of thereof drugs (Li + FA). Manic-like behaviors were assessed in the open-field test. Oxidative stress and inflammation parameters were assessed in the frontal cortex, striatum, and hippocampus. Administration of m-AMPH in rats significantly enhanced the exploratory and locomotor behaviors, as well as the risk-taking and stereotypic behaviors. Li + FA reversed these behavioral alterations elicited by m-AMPH. Administration of this psychostimulant also increased oxidative damage to lipids and proteins, whereas Li + FA reversed these oxidative damages. m-AMPH also induced an increase in the glutathione peroxidase (GPx) activity and a decrease in the glutathione reductase (GR) activity. Li + FA reversed the alteration in GR activity, but not in GPx activity. In addition, m-AMPH increased the IL-1β and TNF-α levels in the rat brain; Li + FA combined therapy reversed the alterations on these inflammatory parameters. FA administration per se reduced the increased TNF-α content induced by m-AMPH. Present study provides evidence that FA is effective as an adjunct to Li standard therapy on manic-like behaviors, oxidative stress and inflammatory parameters in a model of mania induced by m-AMPH.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008297 Male Males
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005492 Folic Acid A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. Pteroylglutamic Acid,Vitamin M,Folacin,Folate,Folic Acid, (D)-Isomer,Folic Acid, (DL)-Isomer,Folic Acid, Calcium Salt (1:1),Folic Acid, Monopotassium Salt,Folic Acid, Monosodium Salt,Folic Acid, Potassium Salt,Folic Acid, Sodium Salt,Folvite,Vitamin B9,B9, Vitamin
D000087122 Mania A state of elevated excitement with over-activity sometimes accompanied with psychotic symptoms (e.g., PSYCHOMOTOR AGITATION, inflated SELF ESTEEM and flight of ideas). It is often associated with mental disorders (e.g., CYCLOTHYMIC DISORDER; and BIPOLAR DISEASES). Hypomania,Hypomanic Episode,Manic Episode,Manic State,Episode, Manic,Hypomanias,Hypomanic Episodes,Manias,Manic Episodes
D000661 Amphetamine A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Desoxynorephedrin,Levoamphetamine,Phenopromin,l-Amphetamine,Amfetamine,Amphetamine Sulfate,Amphetamine Sulfate (2:1),Centramina,Fenamine,Mydrial,Phenamine,Thyramine,levo-Amphetamine,Sulfate, Amphetamine,l Amphetamine,levo Amphetamine
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
July 2020, Progress in neuro-psychopharmacology & biological psychiatry,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
August 2023, Journal of affective disorders,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
September 2006, Journal of psychiatry & neuroscience : JPN,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
June 2013, Progress in neuro-psychopharmacology & biological psychiatry,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
July 1977, The American journal of orthopsychiatry,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
May 2017, Neuropharmacology,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
February 2012, Current neurovascular research,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
December 2022, Pharmacological research,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
October 1967, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Samira Menegas, and Gustavo C Dal-Pont, and José H Cararo, and Roger B Varela, and Jorge M Aguiar-Geraldo, and Taise Possamai-Della, and Monica L Andersen, and João Quevedo, and Samira S Valvassori
February 2011, Journal of psychopharmacology (Oxford, England),
Copied contents to your clipboard!